Highest-materiality recent filing
Xencor reports Q1 net loss $128.9M ($1.71/shr); revenue down to $4.5M from $32.7M
Q1 2026 revenue $4.5M (vs $32.7M Q1 2025), including a $6.6M one-time reduction from Alexion royalty dispute.
XmAb942 achieved 74.1-day half-life; supports single SC dose every 12 weeks during maintenance.
Policy covers VPs (9 months), SVP (12 months), EVP (15 months) and C-level officers, excluding CEO.
Xencor receives Genentech/Roche termination notice for collaboration; effective Sept 4, 2026
Genentech terminated Amended and Restated Collaboration & License Agreement for convenience, effective September 4, 2026.
Alexion refuses further US Ultomiris royalties; Xencor disputes, cuts revenue forecast
Alexion informed Xencor it will not pay additional US royalties on Ultomiris and will cease future US payments.
Xencor Q4 net loss narrows to $6.7M; XmAb819 dose expansion advances; Xtend royalty upside $100-120M
Q4 revenue $28.2M (down 47% YoY), full year $125.6M (up 14%). Net loss $6.7M ($0.09/sh) vs $45.6M prior-year Q4.
Xencor reports $611M cash; outlines 2026 pipeline milestones for XmAb candidates
Unaudited cash, equivalents & marketable debt securities ~$611M as of Dec 31, 2025 vs $706.7M a year ago.
Xencor narrows Q3 net loss to $6M; advances key bispecific antibodies toward pivotal studies
Net loss $6.0M ($0.08 per share) vs $46.3M loss ($0.72) in Q3 2024; revenue $21.0M, up from $17.8M.
Xencor reports 25% ORR for XmAb819 in ccRCC Phase 1; dose-expansion cohort selected
XmAb819 (ENPP3 x CD3) Phase 1: 25% ORR (5/20 PRs) and 70% DCR in target dose range in heavily pre-treated ccRCC.
Xencor Q2 2025 revenue $43.6M, net loss $30.8M; Incyte milestone $25M
Revenue $43.6M (up from $23.9M Q2 2024); net loss $30.8M ($0.41/share) vs $67.3M ($1.09) prior year.
Xencor appoints Raymond Deshaies, Ph.D. to board of directors
Dr. Deshaies is a former SVP of global research at Amgen with 25+ years in biotech.
All eight director nominees elected, including Bassil Dahiyat and Todd Simpson, with >63M votes for each.
Xencor Q1 net loss narrows to $48.4M; CDO Valente resigns, Phase 2b UC study on track
Q1 revenue $32.7M (up from $16.0M YoY); net loss $48.4M (-$0.66 EPS) versus $73.4M (-$1.20 EPS) prior year.
Xencor reports positive interim Phase 1 results for XmAb942; half-life >71 days
XmAb942 well tolerated; no serious AEs, no discontinuations.
Xencor dismisses auditor RSM, appoints KPMG after material weaknesses and restatement
Dismissed RSM on Feb 27, 2025; engaged KPMG effective March 3, 2025.
Xencor appoints former Seagen CFO Todd Simpson to board of directors
Todd Simpson appointed to Xencor board on March 13, 2025, and named to Audit Committee.
Xencor dismisses RSM as auditor over material weaknesses; appoints KPMG
RSM dismissed Feb 27, 2025; KPMG appointed effective Mar 3, 2025.
Xencor Q4 net loss widens to $45.6M; full-year revenue falls 37% to $110.5M
Q4 revenue $52.8M (+3.5% YoY) driven by milestone payments; full-year revenue $110.5M vs $174.6M.
Xencor restates FY2023 and Q1-Q3 2024 results; errors in royalty accounting and tax
Royalty transaction with OMERS Life Sciences misclassified as deferred income instead of debt; impacted balance sheet by ~$168.5M debt understatement.
Preliminary cash & marketable securities ~$707M at Dec 31, 2024, up from $697M in 2023; expected to fund ops into 2028.
Xencor Q3 net loss $45.1M ($0.71 EPS), revenue down 82% YoY; cash $754M
Net loss of $45.1M ($0.71 diluted EPS) vs net loss of $24.3M ($0.40) in Q3 2023.
Xencor director Dagmar Rosa-Bjorkeson will not seek reelection at 2025 Annual Meeting
Dagmar Rosa-Bjorkeson informed board on Sept 30, 2024 of her intent not to stand for reelection.
Xencor prices $175M public offering of common stock and pre-funded warrants
Offering of 6,635,112 shares at $18.00/share and pre-funded warrants for 3,088,888 shares at $17.99 each.
Xencor closes public offering of 8.1M shares at $18, raising ~$201M in gross proceeds
Offering included 8,093,712 shares at $18.00/share and pre-funded warrants for 3,088,888 shares at $17.99/warrant.
Xencor unveils autoimmune pipeline, reports initial XmAb819 RECIST responses in ccRCC
XmAb942 (anti-TL1A) Phase 1 healthy volunteer study starts Q4 2024; interim data in H1 2025.
Xencor Q2 net loss widens to $66M; revenue falls 63% YoY to $17M
Net loss $66.0M ($1.07 diluted EPS) vs $22.0M ($0.37) in Q2 2023; net loss $134M YTD.
Xencor stockholders elect all eight directors, ratify auditor, approve say-on-pay
All eight director nominees elected with >49M votes for; highest vote-getter Dr. Dahiyat with 52.9M for.
Xencor Regains Exclusive Worldwide Rights to Plamotamab After Janssen Termination
Xencor regains worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen terminates its rights.
Xencor Q1 2024 net loss $68.0M ($1.11/share); revenue down to $12.8M from $19.0M
Net loss widened to $68.0M from $60.8M YoY; diluted EPS -$1.11 vs -$1.02.
On May 5, 2025, Nancy Valente, Executive Vice President and Chief Development Officer, notified the Company of her intention to resign from the Company effective June 6, 2025, and remain as a senior advisor.
Todd Simpson was appointed to serve as a new member of the Board of Directors (the “Board”) of Xencor, Inc. (the “Company”).
On September 30, 2024 Dagmar Rosa-Bjorkeson provided notice to the board of directors (the “Board”) of Xencor, Inc. (the “Company”) of her intent not to stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders.
Max materiality 0.90 · Median 0.65 · Most common event other_material